제약 및 바이오테크놀러지 분야 인공지능(AI) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The AI in Pharma and Biotech Market size is expected to reach USD 36.70 Billion in 2034 from USD 10.65 Billion (2025) growing at a CAGR of 14.74% during 2026-2034.

The global AI in pharma and biotech market is experiencing rapid growth as artificial intelligence technologies transform drug discovery, clinical trials, and research processes. AI enables pharmaceutical companies to analyze vast datasets, identify potential drug candidates, and accelerate the development of new treatments. This capability significantly reduces research time and costs, making AI an essential tool in modern pharmaceutical innovation.

Pharmaceutical and biotechnology companies are increasingly partnering with technology firms to integrate AI into their research and development operations. AI applications such as predictive analytics, machine learning, and data modeling are improving the accuracy of drug development and clinical trial outcomes. These technologies are helping organizations optimize research strategies and improve the efficiency of pharmaceutical development.

In the coming years, the market is expected to expand significantly as AI technologies continue to evolve and integrate with advanced biomedical research. Growing investments in digital healthcare and computational biology are further strengthening the role of AI in pharmaceutical innovation. As the demand for faster and more efficient drug development increases, AI adoption in the pharma and biotech sectors is likely to accelerate.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Component

• Software
• Hardware
• Services

By Application

• Drug Discovery
• Clinical Trials
• Personalized Medicine
• Diagnostics
• Others

By Deployment Mode

• On-Premises
• Cloud

By End-User

• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Others

COMPANIES PROFILED

• IBM Watson Health, Google DeepMind, Microsoft Genomics, NVIDIA Corporation, Atomwise, BenevolentAI, Insilico Medicine, Exscientia, BioXcel Therapeutics, CureMetrix, PathAI, Recursion Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY COMPONENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Component
• 4.2. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hardware Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Drug Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinical Trials Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY DEPLOYMENT MODE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Deployment Mode
• 6.2. On-Premises Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cloud Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AI IN PHARMA AND BIOTECH MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Component
  • 8.2.2 By Application
  • 8.2.3 By Deployment Mode
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Component
  • 8.3.2 By Application
  • 8.3.3 By Deployment Mode
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Component
  • 8.4.2 By Application
  • 8.4.3 By Deployment Mode
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Component
  • 8.5.2 By Application
  • 8.5.3 By Deployment Mode
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Component
  • 8.6.2 By Application
  • 8.6.3 By Deployment Mode
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AI IN PHARMA AND BIOTECH INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 IBM Watson Health
  • 10.2.2 Google DeepMind
  • 10.2.3 Microsoft Genomics
  • 10.2.4 NVIDIA Corporation
  • 10.2.5 Atomwise
  • 10.2.6 BenevolentAI
  • 10.2.7 Insilico Medicine
  • 10.2.8 Exscientia
  • 10.2.9 BioXcel Therapeutics
  • 10.2.10 CureMetrix
  • 10.2.11 PathAI
  • 10.2.12 Recursion Pharmaceuticals